Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin

Basic and Clinical Pharmacology and Toxicology

Volumn 97, Issue 4, 2005, Pages 249-256

  Kajosaari, Lauri I ^a   Laitila, Jouko ^a   Neuvonen, Pertti J ^a   Backman, Janne T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; ITRACONAZOLE; MIDAZOLAM; PACLITAXEL; QUERCETIN; RECOMBINANT ENZYME; REPAGLINIDE; RIFAMPICIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BEZAFIBRATE; CARBAMATES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GEMFIBROZIL; HUMANS; HYPOGLYCEMIC AGENTS; ITRACONAZOLE; MICROSOMES, LIVER; MIDAZOLAM; PACLITAXEL; PIPERIDINES; PROCETOFEN; QUERCETIN; RIFAMPIN;

EID: 25844448609     PISSN: 17427835     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2005.pto_157.x     Document Type: Article

References (32)

1. Backman, J. T., C. Kyrklund, K. T. Kivistö, J. S. Wang & P. J. Neuvonen: Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Therap. 2000, 68, 122-129.
2. Bidstrup, T. B., I. Bjørnsdottir, U. G. Sidelmann, M. S. Thomsen & K. T. Hansen: CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Brit. J. Clin. Pharmacol. 2003, 56, 305-314.
3. Bidstrup, T. B., N. Stilling, P. Damkier, B. Scharling, M. S. Thomsen & K. Brøsen: Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur. J. Clin. Pharmacol. 2004, 60, 109-114.
4. Davies, B. & T. Morris: Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10, 1093-1095.
5. Desai, P. B., J. Z. Duan, Y. W. Zhu & S. Kouzi: Human liver microsomal metabolism of paclitaxel and drug interactions. Eur. J. Drug Metab. Pharmacokinet. 1998, 23, 417-424.
6. Gromada, J., S. Dissing, H. Kofod & J. Frakjaer-Jensen: Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995, 38, 1025-1032.
7. Ha, H. R., K. M. Rentsch, J. Kneer & D. J. Vonderschmitt: Determination of midazolam and its alpha-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography. Ther. Drug Monit. 1993, 15, 338-343.
8. Hatorp, V: Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin. Pharmacokinet. 2002, 41, 471-483.
9. Hatorp, V., K. T. Hansen & M. S. Thomsen: Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J. Clin. Pharmacol. 2003, 43, 649-660.
10. Hatorp, V., S. Oliver & C. A. Su: Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int. J. Clin. Pharmacol. Therap. 1998, 36, 636-641.
11. Ishigam, M., M. Uchiyama, T. Kondo, H. Iwabuchi, S. Inoue, W. Takasaki, T. Ikeda, T. Komai, K. Ito & Y. Sugiyama: Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions. Pharm Res. 2001, 18, 622-631.
12. Isoherranen, N., K. L. Kunze, K. E. Allen, W. L. Nelson & K. E. Thummel: Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 2004, 32, 1121-1131.
13. Iwatsubo, T., H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C. E. Green, C. A. Tyson, T. Yokoi, T. Kamataki & Y. Sugiyama: Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes. J. Pharmacol. Exp. Therap. 1997, 282, 909-919.
14. Kajosaari, L. I., J. T. Backman, M. Neuvonen, J. Laitila & P. J. Neuvonen: Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Brit. J. Clin. Pharmacol. 2004, 58, 390-396.
15. Lin, J. H. & A. Y. Lu: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. 1997, 49, 403-449.
16. Niemi, M., J. T. Backman, M. Neuvonen & P. J. Neuvonen: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003a, 46, 347-351.
17. Niemi, M., J. T. Backman, M. Neuvonen, P. J. Neuvonen & K. T. Kivistö: Rifampin decreases the plasma concentrations and effects of repaglinide. Clin. Pharmacol. Therap. 2000, 68, 495-500.
18. Niemi, M., L. I. Kajosaari, M. Neuvonen, J. T. Backman & P. J. Neuvonen: The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Brit. J. Clin. Pharmacol. 2004, 57, 441-447.
19. Niemi, M., J. B. Leathart, M. Neuvonen, J. T. Backman, A. K. Daly & P. J. Neuvonen: Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Therap. 2003b, 74, 380-387.
20. Niemi, M., P. J. Neuvonen & K. T. Kivistö: The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin. Pharmacol. Therap. 2001, 70, 58-65.
21. Ong, C. E., S. Coulter, D. J. Birkett, C. R. Bhasker & J. O. Miners: The xenobiotic inhibitor profile of cytochrome P4502C8. Brit. J. Clin. Pharmacol. 2000, 50, 573-580.
22. Parise, R. A., R. K. Ramanathan, W. C. Zamboni & M. J. Egorin: Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003, 783, 231-236.
23. Plum, A., L. K. Muller & J. A. Jansen: The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma. Meth. Find. Exp. Clin. Pharmacol. 2000, 22, 139-143.
24. Proctor, N. J., G. T. Tucker & A. Rostami-Hodjegan: Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 2004, 34, 151-178.
25. Sabordo, L., B. C. Sallustio, A. M. Evans & R. L. Nation: Hepatic disposition of the acyl glucuronidel-O-gemfibrozil-beta-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation. J. Pharmacol Exp. Therap. 1999, 288, 414-420.
26. Sallustio, B. C., B. A. Fairchild, K. Shanahan, A. M. Evans & R. L. Nation: Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab. Dispos. 1996, 24, 984-989.
27. Shitara, Y., M. Hirano, H. Sato & Y. Sugiyama: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol Exp. Therap. 2004, 311, 228-236.
28. Walsky, R. L., E. A. Gaman & R. S. Obach: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J. Clin. Pharmacol. 2005a, 45, 68-78.
29. Walsky, R. L., R. S. Obach, E. A. Gaman, J. P. Gleeson & W. R. Proctor: Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab. Dispos. 2005b, 33, 413-418.
30. van Heiningen, P. N., V. Hatorp, K. Kramer Nielsen, K. T. Hansen, J. J. van Lier, N. C. De Merbel, B. Oosterhuis & J. H. Jonkman: Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing. Eur. J. Clin. Pharmacol. 1999, 55, 521-525.
31. Wang, J. S., M. Neuvonen, X. Wen, J. T. Backman & P. J. Neuvonen: Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 2002, 30, 1352-1356.
32. Wilkinson, G. R.: Clearance approaches in pharmacology. Pharmacol. Rev. 1987, 39, 1-47.